The Global Immune–Nutrition–Inflammation Index (GINI) as a Candidate Prognostic Marker in Patients with Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab

Abstract

Simple Summary Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Although anti-PD-1 immunotherapy has significantly improved treatment outcomes for patients with advanced disease, a substantial portion of individuals do not respond, and reliable pretreatment tools to predict success are currently lacking. This study explores whether a scoring system called the Global Immune–Nutrition–Inflammation Index (GINI), which combines routine laboratory measurements of inflammation and nutritional status, can predict survival in cSCC. The findings demonstrate that a high GINI score is strongly linked to poorer treatment response and shorter survival. This practical index has the potential to help clinicians identify high-risk patients early and inform risk assessment and clinical monitoring, potentially supporting future treatment planning.